PCM
UBX

Penserra Capital Management’s Unity Biotechnology UBX Stock Holding History

Penserra Capital Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-126
Closed -$3K – 1554
2021
Q3 		$3K Buy
126
+1
+0.8% +$35 ﹤0.01% 1429
2021
Q2 		$5K Buy
125
+4
+3% +$193 ﹤0.01% 1319
2021
Q1 		$7K Sell
121
-1
-0.8% -$68 ﹤0.01% 1064
2020
Q4 		$6K Buy
122
+78
+177% +$3.76K ﹤0.01% 976
2020
Q3 		$1K Buy
+44
New +$2.79K ﹤0.01% 925

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Penserra Capital Management's UBX Position: Q4 2021 in Review

Penserra Capital Management sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 126 shares — an estimated $3K sold.

Penserra Capital Management first reported a position in UBX in Q3 2020 and held it in 5 quarters. The position peaked at $7K in Q1 2021. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

  • Penserra Capital Management reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 126 Unity Biotechnology shares in Q4 2021, an estimated $3K.
  • Penserra Capital Management first reported a position in Unity Biotechnology in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Unity Biotechnology position peaked at $7K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.